EF Hutton Assumes VolitionRX at Buy, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore has assumed coverage of VolitionRX with a Buy rating and set a price target of $5.
August 26, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tim Moore has assumed coverage of VolitionRX with a Buy rating and set a price target of $5, indicating a positive outlook for the stock.
The assumption of a Buy rating and a price target of $5 by EF Hutton suggests a positive outlook for VolitionRX, likely leading to increased investor interest and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100